L&C Bio sets final issue price at 39,100 won for 3,700,000-share rights issue
Bitget2026/10/12 05:45- L&C Bio set the final issue price for its shareholder allocation capital raise at KRW 39,100 per share.
- Transaction covers 3,700,000 common shares with a par value of KRW 500 each.
- Final price reflects the lower of the first-stage price of KRW 39,100 or the second-stage price of KRW 42,400.
- Pricing was fixed on 2026-10-08.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Sui Foundation Invests $30M in DATA Network as It Moves to Sui post-167040 post-167040 post-167040
Equities: Stable oil and yields support stock gains - Danske Bank
Dental caries treatment provider vVardis (VVVV.US) submits US IPO application, expected to raise 200 million USD
vVardis Holding filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC) last Friday. The company focuses on self-developed non-invasive restorative therapies for the early treatment of dental caries. The IPO is expected to raise 200 millions USD.
Nigeria digital bank OPay (OPAY.US) submits IPO application to U.S. stock market: Business covers Egypt, Indonesia, and Pakistan, plans to raise up to 500 millions USD.
OPay has applied for listing on the New York Stock Exchange, aiming to raise up to $500 million. Over the past year, its revenue reached $806 million. OPay holds the top market share among financial apps in Africa and the Middle East, with a market share of 9.9%.
Crypto prices
More
